Goals & Objectives. Disclosure. Abbreviations. New and Emerging Chemotherapies 3/2/ Author has nothing to disclose
|
|
- Annabel Wilkerson
- 6 years ago
- Views:
Transcription
1 Goals & Objectives New and Emerging Chemotherapies Luis Hernandez PGY-1 Pharmacy Resident University of Miami Hospital Distinguish key differences between new oral and parenteral chemotherapies Pharmacists: Discuss relevant side effects of new oral and parenteral chemotherapies Technicians: Discuss proper handling and storage of new oral and parenteral chemotherapies Learn about immunotherapies in Hematology/Oncology Pharmacists: Review recent FDA approvals of immunotherapies Technicians: Review preparation of recently approved immunotherapies Recognize and analyze the drugs and trends in the Hematology/Oncology pipeline Pharmacists, Technicians: Examine the most promising pipeline drugs 3 Disclosure Abbreviations Author has nothing to disclose 2 AE: Adverse event APC: Antigen presenting cell CA: Cancer CINV: Chemotherapy Induced Nausea & Vomiting CTLA-4: Cytotoxic T- lymphocyte-associated protein 4 GI: Gastrointestinal GM-CSF: Granulocyte macrophage colony stimulating factor PD-1: Programmed death receptor 1 PD-L1: Programmed death ligand 1 HR: Hormone receptor HSV: Herpes Simplex Virus IL: Interleukin NSCLC: Non small cell lung cancer PFUs: Plaque forming units TNF: Tumor necrosis factor 4 1
2 Immunotherapy AWP per vial Price of treatment for 1 year (70 kg pt) Darzalex (daratumumab) 100 mg/5 ml= $ mg/20 ml= $2,160 $149,000 New Chemotherapies Oral vs. Parenteral 5 Empliciti (elotuzumab) Imlygic (talimogene laherparepvec) 300 mg=$2, mg= $2,842 1,000,000 units/ml= $ ,000,000 units/ml= $5,280 $149,000 2 ml per visit for 6 months: ~$253,000 Unituxin (dinutuximab) 17.5 mg/5 ml= $9,000 **Peds pt w/ BSA= 1: $180,000 Oral chemos AWP for 30 day supply Price of treatment for 1 year Odomzo (sonidegib) $12,072 $144,864 Cotellic (cobimetinib) $7,274 $87,288 Ibrance (palbociclib) $12,411 $148,932 Tagrisso (osimertinib) $15,300 $183,600 Alecensa (alectinib) $14,793 $177,516 Lenvima (lenvatinib) $5,776 $69,312 Farydak (panobinostat) $8,800 (21 day cycle) $140,800 (16 cycles) Ninlaro (ixazomib) $10,404 $124, FDA Approvals Ibrance(palbociclib) Drug Indication Drug Indication Odomzo (sonidegib) Basal cell CA Alecensa (alectinib) NSCLC Ibrance (palbociclib) Breast CA Tagrisso (osimertinib) NSCLC Lonsurf (tipiracil/trifluridine) Yondelis (trabectedin) Imlygic (talimogene laherparepvec) Colorectal CA Liposarcoma or leiomyosarcoma Portrazza (necitumumab) NSCLC Unituxin (dinutuximab) Neuroblastoma Melanoma Lenvima (lenvatinib) Thyroid CA Cotellic (cobimetinib) Melanoma Varubi (rolapitant) CINV Farydak (panobinostat) Multiple Myeloma Empliciti (elotuzumab) Multiple Myeloma Ninlaro (ixazomib) Multiple Myeloma Darzalex (daratumumab) Multiple Myeloma Advanced breast cancer (HR+, HER-2 negative) o First-line in combination with Femara (letrozole) o Second-line with Faslodex (fulvestrant) 125 mg PO daily for 21 days, then 7 off (with food) Bone marrow suppression, GI toxicity, infections and thromboembolic events Major CYP3A4 substrate FDA Novel Drug Approvals for [ONLINE] Available at: [Accessed 2/4/16]. 6 Ibrance (palbociclib) [prescribing information]. New York, NY: Pfizer Labs; February
3 Ibrance(palbociclib) Farydak(panobinostat) m/buy-ibrance-palbociclibbreast-cancer-pfizer.html. Accessed 2/12/16 /drug/34436/. Accessed 2/12/16 Accessed 2/12/ &course=181&nocredit=1&token=33d2a02765b2ed16e7848cbdcf98ea0a. Accessed 2/12/ Farydak(panobinostat) Multiple Myeloma (with bortezomib, dexamethasone) 20 mg PO every other day for 3 doses/week (D1, 3, 5, 8, 10, 12) of weeks 1, 2 of each 21-day cycle x 8 cycles Boxed Warnings: Diarrhea & cardiovascular events Moderate emetogenic potential CYP3A4 substrate; moderate CYP2D6 inhibitor Ninlaro(ixazomib) Multiple Myeloma (with lenalidomide, dexamethasone) 4 mg POweekly on Days 1, 8, 15 of each 28-day cycle Take 1 hour prior or 2 hours after eating CrCl < 30 ml/min or dialysis-decrease dose to 3 mg Hematologic, dermatologic, GI toxicities, neuropathies Farydak (panobinostat) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February Ninlaro (ixazomib) [prescribing information]. Cambridge, MA: Takeda Pharmaceutical Company Limited; November
4 Ninlaro(ixazomib) Empliciti (elotuzumab) o-ixazomib-treatment-multiplemyeloma/. Accessed 2/12/16 ticles/112247/ /fda -gives-approval-to-bloodcancer-drug-empliciti.htm. Accessed 2/12/16 Accessed 2/12/ Accessed 2/12/16 15 Empliciti (elotuzumab) Darzalex (daratumumab) Multiple myeloma (relapsed/refractory) with lenalidomide and dexamethasone Cycle 28-Day Cycles 1 & 2 28-Day Cycles 3+ Day of Cycle Empliciti (mg/kg) IV Lenalidomide (25 mg) PO Days 1-21 Days 1-21 Dexamethasone (mg) PO Dexamethasone (mg) IV Interferes with serological testing Higher incidence of second primary malignancies Empliciti (elotuzumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; November Multiple Myeloma (relapsed/refractory): Single agent 16 mg/kg IV weekly (1-8), q2 weeks (9-24), q4 weeks Delayed infusion reactions Prophylaxis for Herpes Zoster Virus is recommended: 1 week prior and for 3 months after treatment Refrigerate for up to 24 hours and protect from light Interferes with serological testing Darzalex (daratumumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; November
5 Darzalex (daratumumab) Imlygic (talimogene laherparepvec) Do not administer to immunocompromised, pregnant Store and transport at -90 C to -70 C Protect from light Accessed 2/12/16 Common adverse events: fatigue, chills, pyrexia, nausea Limitation: Has not been shown to improve overall survival or have an effect on visceral metastases Accessed 2/12/16 17 Imlygic (talimogenelaherparepvec) [prescribing information]. Thousand Oaks, CA: BioVex, Inc; October Imlygic (talimogene laherparepvec) Imlygic(talimogene laherparepvec) Genetically modified, live attenuated, herpes simplex virus 1 oncolytic virus Indication: Unresectable melanoma Dosing: o Initial visit: Inject up to 4 ml of 10 6 PFUs/ml intralesionally o Second visit: Inject up to 4 ml of 10 8 PFUs/ml intralesionally (3 weeks after initial) o Future visits: Inject up to 4 ml of 10 8 PFUs/ml intralesionally every 2 weeks for at least 6 months Imlygic (talimogenelaherparepvec) [prescribing information]. Thousand Oaks, CA: BioVex, Inc; October
6 Initiation of Immune Response The Future of Cancer Treatment: Immunotherapies Antigen Antigen fragments Naive T-cell Antigen receptors Effector cells: 1. Activate other immune cells 2. Kill target cells Antigen presenting cell (APC) Activated T-cell Memory cells: 1. Circulate for months years 2. Ready to rapidly respond to same antigen again Antigen Activated recognition APC Activation T-cell interaction T-cell activation Replication of antigenspecific T-cells T-cells become specialized Lymphoid Organs 21 Abbas AK, Lichtman AH. Basic Immunology. 3rd ed Peripheral Tissues 23 Cancer Pathogenesis Immune Cells in Tumors Deregulating cellular energetics Avoiding immune destruction Evading growth suppressors Hallmarks of Cancer Pathogenesis (2011) Activating invasion and metastasis Enabling replicative immortality OS (%) T-cell infiltration within tumors is associated with overall survival (OS) in patients with different cancers Kaplan-Meier Curve for OS in Advanced Ovarian Cancer 1 P<0.001 Intratumoral T cells (n=102) Median OS = 50.3 months Sustaining proliferative signaling Resisting cell death Inducing angiogenesis 25 0 No intratumoral T cells (n=72) Median OS = 18 months n=102 Month Hanahan D, Weinberg RA. Cell. 2011;144(5): Zhang L, Coukos G, et al. N Engl J Med. 2003;348(3):
7 What is Immunotherapy? Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases Examples in cancer: 1) Checkpoint inhibitors 2) Monoclonal antibodies 3) Therapeutic cancer vaccines 4) Cytokines Immunotherapy: Treatment Considerations Relative efficacy may be greater with lower tumor burden Patient given immunotherapy earlier in disease may have better outcomes Tumor Burden A B Tumor Growth Rate Expected clinical outcome if no treatment is provided A B Death Patient given a vaccine earlier Patient given a vaccine later Time National Cancer Institute. Cancer terms. Accessed 1/15/ Gulley JL, Drake CG. ClinCancer Res. 2011;17(12): Cancer Type Checkpoint Inhibitors Monoclonal Antibodies Cancer Vaccines Oncolytic Virus Bladder Brain Breast Cervical Colorectal Esophageal Head and Neck Kidney Leukemia Liver Lung Lymphoma Melanoma *** Multiple Myeloma Ovarian Pancreatic Prostate Sarcoma Adapted from Checkpoint Inhibition Accessed 2/2/
8 OPDIVO (nivolumab) Takes the foot off the brakes YERVOY (ipilimumab) Accessed 2/2/ KEYTRUDA (pembrolizumab) Immune-Mediated Adverse Effects Rare immune-mediated side effects: o Pneumonitis o Colitis o Hepatitis o Nephritis and Renal Dysfunction o Hypothyroidism and Hyperthyroidism Treatment: o Hold or permanently discontinue depending on severity o Steroids (prednisone 1-2 mg/kg daily or equivalent) expression-can-id-best-responders-mercks-anti-pd-1. Accessed 2/12/
9 Monitoring Parameters 1) Hepatic and renal function tests (baseline, periodic) 2) Thyroid function tests (baseline and every 6 weeks) 3) Blood glucose (hyperglycemia) 4) Rash, diarrhea, adrenal insufficiency 5) CBC, platelets 100,000, ANC 1.5(baseline, weekly) 6) Infusion reactions Nivolumab Infusion Vials must be refrigerated and protected from light Prepared in NS or D5W; 10 mg/ml vial 1-10 mg/ml 3 mg/kg IV q2weeks; 1 mg/kg IV q3weeks x 4 with ipilimumab; no premedicationsrequired Storage after preparation: Room temperature-no more than 4 hours Refrigeration- no more than 24 hours IV line musthave a sterile, non-pyrogenic, low protein binding micron in-line filter; infuse over 60 mins 33 Opdivo (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; January Pembrolizumab Infusion Vials must be refrigerated and protected from light Prepared in NS or D5W; 100 mg/4ml vial 1-10 mg/ml 2 mg/kg IV q3weeks; no premedicationsrequired Storage after preparation: Room temperature-no more than 6 hours Refrigeration- no more than 24 hours IV line musthave a sterile, non-pyrogenic, low protein binding micron in-line filter; infuse over 30 mins Ipilimumab Infusion Vials must be refrigerated and protected from light Prepared in NS or D5W; 5 mg/ml vial 1-2 mg/ml 3 mg/kg IV q3weeks x 4 doses MAX Storage after preparation: no more than 24 hours IV line musthave a sterile, non-pyrogenic, low protein binding micron in-line filter; infuse over 90 mins Opdivo (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; January Yervoy (ipilimumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; October
10 Patient Case Management of Diarrhea 55 year old woman with metastatic melanoma Started Opdivo (Nivolumab) 3 mg/kg IV q2weeks She comes to clinic 4 weeks later complaining of diarrhea, which was occasionally bloody She took some Imodium (loperamide) for several days with no results 37 O Day, et al. Cancer 2007;110: Patient Case Managing Adverse Events How do you proceed? a) Refer her to the emergency department for IV hydration and steroids; dicontinue nivolumab b) Counsel patient that this is normal and may be related to her diet; continue nivolumab c) Obtain a full history of the diarrhea and recommend a strict diet, oral hydration; continue nivolumab d) Recommend oral steroids x 5 days, followed by a month long taper; continue nivolumab e) Discontinue nivolumab and the diarrhea will stop 38 Any Grade 1 AE or isolated hypothyroidism Symptom management or replacement therapy for hypothyroidism Continue PD-1 treatment and monitor Nivolumab immune mediated adverse reactions management guide. d?file=00pi000000gl6roeal. Accessed February A Guide to Monitoring Patients During Treatment with Pembrolizumab: A Resource for Adverse Reaction Management. Available at: Accessed February 2016 Grade 2 colitis, nephritis, hepatitis or pneumonitis Symptomatic hypophysitis Any Grade 3 AE Hold PD-1 treatment and administer steroids Improve to Grade 1: Taper steroids for 1+ month Resume if: Grade 0/1 AE after steroid taper Permanently discontinue if: No improvement within 12 weeks Cannot taper steroids 40 within 12 weeks 10
11 Managing Adverse Events Grade 3 or 4 pneumonitis or nephritis Grade 3 or 4 infusion reaction Any life-threatening or Grade 4 adverse event Any severe or recurrent Grade 3 adverse event What does the future hold? Initiate steroids and permanently discontinue checkpoint inhibitor Nivolumab immune mediated adverse reactions management guide. vlet.filedownload?file=00pi000000gl6roeal. Accessed February A Guide to Monitoring Patients During Treatment with Pembrolizumab: A Resource for Adverse Reaction Management. Available at: Accessed February 2016 Hepatitis with: AST/ALT > 5x ULN AST/ALT 50% from baseline Total bilirubin> 3x ULN Key Role for Pharmacists Discuss Med Rec findings with physician (monitor autoimmune disease and/or immunosuppression) Monitor toxicities, especially dermatologic and GI Anticipate drug-drug interactions Evaluate costs/acquisition Immunotherapy takes time to work Selinexor SINE (selective inhibitor of nuclear export) Oral agent active in highly aggressive lymphomas Inhibits I-ĸB export Other applications: o HIV, influenza o Autoimmune diseases o Surgical wound healing 42 Multiple Myeloma Research Foundation What is Selinexor (KPT-330)?. [ONLINE] Available at: [Accessed 2/10/16] Image:
12 Acalabrutinib 2 nd -generation inhibitor of Bruton styrosine kinase (BTK) for relapsed CLL 95% overall response rate; 100% in 17p deletion More selective, irreversible inhibition of BTK Improved safety profile compared to ibrutinib: o No major hemorrhage, AFib, tumor lysis, pneumonitis o Headache, diarrhea and weight gain were most common Byrd JC, Harrington B, O Brien S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med Jan 28;374(4): Take Home Points There were 16 Hematology/Oncology drugs approved by the FDA in 2015 Although only 20% of patients respond to immunotherapy, responses are long lasting Immune mediated reactions from PD-1 and CTLA-4 inhibitors can be managed with steroids Starting immunotherapy earlier in the disease course leads to better outcomes 47 Multikine (Leukocyte Interleukin, Injection) Combination of cytokines (IL-1, IL-2, IL-6, TNF-α, etc.) Combination immunotherapy: Has both active and passive immunity with no outside antigens required Currently in global Phase III trial for head & neck cancer o First-line treatment for 3 weeks immediately after diagnosis o Before any standard of care therapies o Phase 2 results: reduced or eliminated all signs of tumor before surgery, radiation and/or chemotherapy True/False Questions 1) The trend toward immunotherapies in Hematology/Oncology describes medications that boost the immune system to fight against malignancy 2) Orally administered chemotherapies are safer than those administered intravenously 3) Imlygic (talimogene laherparepvec) is a first in class oncolytic virus that uses HSV-1 along with GM-CSF and is injected directly into melanoma lesions 4) Imlygic (talimogene laherparepvec) should be stored in a refrigerator (2 C - 8 C) CEL-SCI What is the investigational therapy Multikine (Leukocyte Interleukin, Injection)?. [ONLINE] Available at: [Accessed 2/12/16]
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES REAL PATIENT; ANN (ALIAS) 63 year old woman who smoked for 25 years, quit 15 years ago. Complained
More informationClinical Therapeutic Intelligence Report: 2015 Year in Review
Clinical Therapeutic Intelligence Report: 2015 Year in Review This issue highlights the many ground-breaking therapies approved by the U.S. Food and Drug Administration over the course of 2015. Highlights
More informationUpdates in Hematology
Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,
More informationNivolumab and Ipilimumab
Nivolumab and Ipilimumab Indication Advanced (unresectable or metastatic) melanoma. (NICE TA400) ICD-10 codes Codes prefixed with C43 Regimen details Cycles 1-4 Nivolumab and Ipilimumab every 3 weeks Day
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
Nivolumab (Opdivo ) for treatment of advanced melanoma and Renal Cell Cancer (Also advanced/ metastatic NSCLC EMAS patients only -Nov 2016) DRUG ADMINISTRATION SCHEDULE (SINGLE AGENT Day Drug Daily dose
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationPharmacy Accreditation
The Evolving Role of Specialty Pharmacists in Cancer Immunotherapy: New Pathways, Agents, Opportunities, and Challenges Patrick J. Medina, PharmD, BCOP Professor Department of Medicine Stephenson Cancer
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationA Review of Newly Approved Antineoplastic Medications LISA NARVESON, PHARM D ASSISTANT PROFESSOR OF PRACTICE NORTH DAKOTA STATE UNIVERSITY
A Review of Newly Approved Antineoplastic Medications - 2015 LISA NARVESON, PHARM D ASSISTANT PROFESSOR OF PRACTICE NORTH DAKOTA STATE UNIVERSITY Acknowledgements Hanan Alameddin, Pharm D, MSc Jane Loueng,
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma (PRINCETON,
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationLimitations of Use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.66 Subject: Imlygic Page: 1 of 5 Last Review Date: June 22, 2017 Imlygic Description Imlygic (talimogene
More informationUMN request : information to be made public Page 1
Product Name Active substance Opdivo Nivolumab (BMS 936558) UMN request : information to be made public Page 1 Indication and conditions of use Nivolumab (Opdivo)) is registered by the EMA for the treatment
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationNursing Perspective on iraes: Patient Education, Monitoring and Management
Nursing Perspective on iraes: Patient Education, Monitoring and Management Rebecca Lewis, CRNP Nurse Practitioner University of Pittsburgh-HCC Shadyside Disclosures No relevant financial relationships
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)
September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,
More informationFDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer
March 5, 2015 FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer (PRINCETON, NJ, March 4, 2015) Bristol-Myers Squibb Company
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationAttached from the following page is the press release made by BMS for your information.
September 17, 2015 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma (PRINCETON, NJ, September
More informationATEZOLIZUMAB (TECENTRIQ )
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationNew Cancer Drug Update 2015/2016. Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN
New Cancer Drug Update 2015/2016 Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN Disclosures No conflicts to disclose Objectives Identify new drugs that were FDA approved for
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationAtezolizumab Non-small cell lung cancer
Systemic Anti Cancer Treatment Protocol Atezolizumab Non-small cell lung cancer PROTOCOL REF: MPHAATNSCLC (Version No: 1.0) Approved for use in: Locally advanced/metastatic non squamous or squamous non-small
More informationAttached from the following page is the press release made by BMS for your information.
June 22, 2015 European Commission Approves Bristol-Myers Squibb s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced
More informationImmune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington
More informationMelanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management
Melanoma Immunotherapy Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management Mike Buljan, NP UCSF Medical Center Melanoma Oncology Disclosures None Only FDA-approved
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationCancer Immunotherapy Future from the Past?
Disclaimer This talk is intended for educational value, and includes comments on unlicensed drugs. Please liaise with a specialist if you have a clinical query. Cancer Immunotherapy Future from the Past?
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationHealthcare Professional. Frequently Asked. Questions. Brochure
YERVOY (ipilimumab) Healthcare Professional Frequently Asked Questions Brochure YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. 1 This medicinal product
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More information(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
More informationAttached from the following page is the press release made by BMS for your information.
September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationPembrolizumab 200mg Monotherapy
Pembrolizumab 200mg This regimen supercedes NCCP Regimen 00347 Pembrolizumab 2mg/kg as of September 2018 due to a change in the licensed dosing posology. INDICATIONS FOR USE: INDICATION ICD10 Regimen Code
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively. See full prescribing information for OPDIVO. OPDIVO (nivolumab) injection,
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Nivolumab SYNONYM(S): COMMON TRADE NAME(S): OPDIVO CLASSIFICATION: miscellaneous Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION:
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 4 Last Review Date: March 18, 2016 Yervoy Description Yervoy (ipilimumab)
More informationCheckpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives
Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity Adam J. DiPippo, PharmD Clinical Pharmacy Specialist Leukemia Texas Society of Health-System Pharmacists 2017 Annual Seminar April
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationImmune-Related Adverse Reaction (irar) Management Guide
REGIMEN Immune-Related Adverse Reaction (irar) Management Guide OPDIVO as monotherapy is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) with progression
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationDra. Omayra Reyes, MD. Hematologist- Oncologist. Introduction to Immuno Oncology
Dra. Omayra Reyes, MD. Hematologist- Oncologist Introduction to Immuno Oncology Disclosure I have no conflicts of interest Objectives Review Basic concepts of onco- immunology. Recognize different mechanisms
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationImmuno-Oncology: Essentials for Nurses in Cancer Care
Immuno-Oncology: Essentials for Nurses in Cancer Care BERNADINE O LEARY RN, MN, CON (C) CLINICAL EDUCATOR, EASTERN HEALTH CANCER CARE PROGRAM COURSE FACILITATOR- EASTERN HEALTH ADULT CHEMOTHERAPY COURSE
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationTalimogene Laherparepvec (T-VEC) at the SCCA: an update
Talimogene Laherparepvec (T-VEC) at the SCCA: an update Jennifer M. Gardner, MD Assistant Professor, Division of Dermatology University of Washington jen1110@uw.edu Northwest Melanoma Symposium: Science
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab Protocol Code Tumour Group Contact Physician USMAVNIV Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationManaging immune related toxicity. Karijn Suijkerbuijk May 27 th 2017
Managing immune related toxicity Karijn Suijkerbuijk May 27 th 2017 Disclosures Advisory role: BMS, Merck Travel support: Amgen, Novartis, Roche Whybother? Patients are dying from toxicity Eggermont ipilimumab
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationBristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma
December 2, 2015 Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma (PRINCETON, NJ, November 27, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced that the
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationNew Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More information